O’Melveny & Myers LLP advised Urovant Sciences on the deal. Urovant Sciences announced its US$681 million definitive merger agreement with Sumitovant Biopharma. According to the terms…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
